Access
To read this story in full you will need to login or make a payment (see right).
Outlook
Nature 449, 176-179 (13 September 2007) | doi:10.1038/449176a; Published online 12 September 2007
Open Innovation Challenges
-
Direct Molecular Detection of Proteins and Nucleic Acids
This Challenge is looking for novel approaches to protein and nucleic acid detection. This is an Id...
-
Single-cell Analysis Platform
This Challenge is looking for novel approaches to analyzing changes at a single-cell level. This is...
- More Challenges
- Powered by:
nature jobs
Assistant Professor of Medicine
- Massachusetts General Hospital
- Boston, MA
Lectureship in Ecology
- University of Southampton
- Southampton, Hampshire, SO16 7PX, UK
Neglected Diseases At what price?
Patricia M. Danzon1
Abstract
Differential pricing could make global medicines affordable in developing countries. But drugs for diseases that have no market in the developed world will require additional subsidies, says Patricia M. Danzon.
For the general population in developing nations to have appropriate access to medicines, existing drugs must be affordable, and innovation is needed to develop new medicines. But this presents a potential conundrum: prices that are high enough to pay for research and development (R&D) may make medicines unaffordable in developing regions.
To read this story in full you will need to login or make a payment (see right).
